Phaseline

Targets › VEGFR

VEGFR: drug programs, companies and trials

7 programs from 7 companies in 7 trials: 7 Phase 2; Oncology, Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: the race on VEGFR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jiangxi Provincial Cancer HospitalAnlotinib hydrochloride
Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, RET, KIT)
VEGFR, FGFR, RET, KITPhase 2Esophageal Squamous Cell CarcinomaNov 2026
University of UtahXL092 (Zanzalintinib)
Multi-target kinase inhibitor targeting FGFR, VEGFR, and KIT
FGFR, VEGFR, KITPhase 2Metastatic Castration-resistant Prostate CancerDec 2026
Sun Yat-sen UniversityAnlotinib Hydrochloride
Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET
VEGFR, PDGFRA, PDGFRB, FLT1, KITPhase 2GlioblastomaDec 2026
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAnlotinib hydrochloride
Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR inhibitor)
VEGFR, FGFR, PDGFRPhase 2Sarcoma,Soft TissueDec 2027
Eye & ENT Hospital of Fudan UniversityAnlotinib Hydrochloride
Multi-target tyrosine kinase inhibitor
VEGFR, FGFR, RET, KITPhase 2Adenoid Cystic CarcinomaJun 2028
Yu WangDonafenib
Multikinase inhibitor targeting BRAF, VEGFR, and FLT3
BRAF, VEGFR, FLT3Phase 2Thyroid Cancer–
West China HospitalDonafenib
Multi-targeted tyrosine kinase inhibitor targeting RAF, VEGFR, and FLT3
RAF, VEGFR, FLT3Phase 2Locally Advanced Thyroid Gland Carcinoma–

Conditions

Glioblastoma (1) Thyroid Cancer (1) Esophageal Squamous Cell Carcinoma (1) Locally Advanced Thyroid Gland Carcinoma (1) Metastatic Castration-resistant Prostate Cancer (1) Adenoid Cystic Carcinoma (1) Sarcoma,Soft Tissue (1)

Modalities

small molecule (6), antibody (1)

Companies

Sun Yat-sen University (1) Yu Wang (1) Jiangxi Provincial Cancer Hospital (1) West China Hospital (1) University of Utah (1) Eye & ENT Hospital of Fudan University (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)

Related targets

KIT (4) FGFR (4) FLT3 (2) RET (2) PDGFRA (1) PDGFRB (1) FLT1 (1) BRAF (1) RAF (1) PDGFR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.